RAPID CITY — A federal judge has dismissed three lawsuits brought by pharmaceutical manufacturers and their trade association aimed at overturning South Dakota’s 2025 amendment governing how discounted medicines under the federal 340B program are delivered, keeping the state law in force, state officials said Monday.
Court leaves state law untouched
The suits, filed by AbbVie, AstraZeneca and the Pharmaceutical Research and Manufacturers of America, argued that the state amendment improperly limited the ability of manufacturers and wholesale distributors to impose conditions on contracts between 340B-eligible health care providers and the pharmacies that dispense discounted drugs.
A U.S. District Court dismissed the three complaints, according to a statement from Attorney General Marty Jackley. The ruling means the provision that allows eligible providers to choose how discounted medications arrive — including direct shipment to designated pharmacies — remains legally enforceable in South Dakota.
"a victory for healthcare providers and patients"
Jackley described the decision as a win for patients and providers, saying it will help ensure clinics and pharmacies that serve rural, Native American and other underserved communities continue to receive discounted medicines without interference. The attorney general’s office announced the court’s action Monday.
What the law does and who it affects
The federal 340B program obligates drugmakers to offer lower-cost medications to qualifying health systems and care sites that serve vulnerable populations. South Dakota’s amendment clarifies that eligible providers may determine delivery arrangements with pharmacies without being blocked or restricted by manufacturers or distributors.
State officials and provider advocates argued the change prevents supply-chain practices that could deny communities access to discounted drugs, particularly in remote areas where local pharmacies play a central role in patient care.
- Eligible providers include clinics that serve rural, Native American and underserved populations.
- Delivery flexibility allows providers to have discounted drugs shipped directly to chosen pharmacies.
- Industry challenge came from two major manufacturers and PhRMA, which contended the state law unlawfully interfered with manufacturer-distributor contracts.
Legal and practical implications
By dismissing the complaints, the court effectively leaves intact South Dakota’s protections for 340B arrangements. Providers who rely on the program now retain the state-backed authority to arrange delivery without facing state-level restrictions imposed by manufacturers or distributors.
Legal observers say the ruling could have wider significance if similar state laws are adopted elsewhere or if manufacturers pursue other legal avenues. For now, South Dakota’s clinics and pharmacies that participate in 340B can continue their operations under the framework established by the 2025 amendment.
| Party | Role | Court outcome |
|---|---|---|
| AbbVie | Manufacturer / plaintiff | Complaint dismissed |
| AstraZeneca | Manufacturer / plaintiff | Complaint dismissed |
| PhRMA | Trade group / plaintiff | Complaint dismissed |
Reactions and next steps
State leaders framed the court’s decision as a defense of local access to affordable prescriptions. Providers in remote parts of South Dakota and tribal communities often point to logistical barriers in obtaining medications; the law’s supporters said the amendment addresses those challenges by preserving delivery options.
Pharmaceutical manufacturers had argued the law could disrupt commercial relationships and undermine established distribution practices. With the dismissal, the companies may consider appeals or alternative legal strategies, but for the moment the state’s statute remains operative.
For patients and providers in South Dakota, the immediate effect is continuity: clinics that depend on the discounted-pricing mechanism will not have to alter their delivery arrangements in response to the dismissed suits. Health care organizations that participate in 340B should monitor any further filings or appeals to understand whether future court actions could change the legal landscape.
Attorneys general and state officials often intervene in matters involving federal programs when they believe state statutes protect residents’ access to services. This ruling underscores the continuing tension between manufacturers and some states over how 340B discounts are administered and delivered.
Legal documents in the case and detailed orders from the court have not been released publicly with the attorney general’s announcement. Interested providers and patients can contact the South Dakota Attorney General’s Office for additional information on the state’s position and the court’s dismissal.
